Loading…
Kyntra Bio Inc
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
▼ -97.5% over 5Y.
today you would have $27.16▼ -97.3%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 12 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $8.78 | $13.25 | $22.15 | $400.50 | $352.50 | $927.25 | $1,072.25 | $1,157.00 | $1,185.00 | $535.00 | $761.75 | $683.50 | |
| P/E | — | 0.2x | — | — | — | — | — | — | — |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| BCTXBriaCell Therapeutics Corp. | $3.73 | — | 1.1x | — | -175.25% | $32.45M |
| CCELCryo Cell International Inc | $4.00 | — | — | 15.00% | — | $32.25M |
| IGCIGC Pharma, Inc. | $0.31 | — | 5.2x | — | -83.34% | $32.05M |
| RMTIRockwell Medical Inc | $8.17 |
Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers. It is also developing Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was formerly known as FibroGen, Inc. and change its name to Kyntra Bio, Inc. in January 2026. Kyntra Bio, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Company description provided by Yahoo Finance.
| — |
| — |
| — |
| — |
| P/S | 10.6x | 5.5x | 1.8x | 1.9x | 10.7x | 5.6x | 19.3x | 14.7x | 18.6x | 29.9x | 7.5x | 10.5x | 11.7x |
| P/B | 7.6x | — | — | — | — | 6.3x | 8.0x | 7.3x | 7.8x | 7.4x | 8.8x | 10.7x | 7.3x |
| EPS | $45.37 | -$11.89 | -$73.00 | -$78.50 | -$78.50 | -$52.75 | -$22.25 | -$25.75 | -$41.50 | -$23.25 | -$35.50 | -$79.25 |
| Profit margin | -69.86% | 2848.63% | -160.63% | -607.29% | -208.66% | -123.25% | -107.36% | -30.00% | -40.58% | -92.27% | -31.70% | -47.44% | -43.24% |
| ROE | -32.07% | — | — | — | — | -138.67% | -44.84% | -14.91% | -16.97% | -22.87% | -37.26% | -48.31% | -26.88% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| 0.9x |
| — |
| -15.53% |
| $32.93M |
| ATNMActinium Pharmaceuticals, Inc. | $1.01 | 2.9x | 1.0x | — | 45.86% | $31.69M |
| NNVCNanoviricides Inc | $1.24 | — | 2.9x | — | -89.97% | $31.65M |